Surmounting all the challenges, 1st cell therapy approval in solid tumors is anticipated by 2022.
The spectacular success of cell therapies observed in heme tumors is not yet realized in solid tumors, however, stepped-up efforts to defeat unyielding tumor micro-environment and mechanisms of cell therapy dysfunction have started to bear fruits. Innovative approaches to engineer cell therapies from diverse immune cell sources e.g. adoptive TILs, CAR-T cells, TCR T cells, gamma delta T cells, NK cells, and macrophages have begun to show durable benefit. Early promise is noted in high unmet need, difficult to treat tumors where established agents and even immunotherapies have failed to generate optimal responses.
If you have already placed the bets on cell therapies in the solid tumor franchise and want to stay ahead of the curve or if you are planning to invest but want to test the waters before embarking, then together let’s explore the veracity of cell therapy’s disruptive potential and strategic, stepwise approach to identify the most attractive opportunities to focus on.
FutureBridge’s Oncology Analysts in this webinar will cover:
Share your focus area or question to engage with our Analysts through the Business Objectives service.Submit My Business Objective
Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.